XAIR News & Events

Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement. "While the proposed transaction will not proceed, Beyond Air remains committed to maximizing the value of the NeuroNOS platform," said Steve Lisi, CEO. "We continue to believe NeuroNOS represents a compelling opportunity based on its proprietary small-molecule platform and development programs targeting neurological disorders and oncology." Beyond Air will continue to evaluate strategic alternatives for NeuroNOS and remains focused on advancing its core nitric oxide platform and LungFit programs

Beyond Air commented on the publication of an independent review article providing the most comprehensive overview to date of high-dose inhaled nitric oxide, iNO, delivered at concentrations well above the FDA-approved 20 ppm, and presenting mounting evidence that high-dose iNO may function as a novel broad-spectrum antimicrobial therapy for a wide range of respiratory infections. Titled "The therapeutic potential of high-dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions," the article was published in Intensive Care Medicine Experimental, a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG. "We are excited to see the scientific community increasingly recognize high-dose iNO as a potential game-changing antimicrobial platform for respiratory infections," said Steve Lisi, Chief Executive Officer of Beyond Air. "A growing collection of studies shows that high-dose iNO can address pathogens and clinical challenges that current therapies are unable to treat. This most recent article builds on the momentum of our own clinical programs that have demonstrated promising signals in NTM, bronchiolitis, community-acquired pneumonia, and COVID-19. We believe the publication of this article will serve as a catalyst for new scientific research and accelerate the clinical development of high-dose iNO as a potential transformative treatment modality for pulmonary indications."

Reports Q3 revenue $2.19M, consensus $2.15M. "We exceeded $2.0 million in quarterly revenue which marks an important milestone as we continue scaling our business and building awareness of the benefits our tankless NO system delivers in real-world settings," said Steve Lisi, Chief Executive Officer of Beyond Air. "Our commercial performance reflects steady momentum, with 21% sequential quarterly growth and a 105% increase over the same quarter last year. We will continue to grow our business with LungFit PH as we prepare for the FDA clearance of our second-generation LungFit PH system, which we expect to receive before the end of calendar 2026, subject to regulatory review. We believe the significant enhancements, including reduced weight and footprint, simplified operation, longer service interval, and full compatibility with both air and ground transport, will dramatically accelerate market share gains and position Beyond Air as a global leader in hospital-based NO delivery."